Risedronic Acid (Actonel)

A pyridine and diphosphonic acid derivative that acts as a CALCIUM CHANNEL BLOCKER and inhibits BONE RESORPTION.

Also Known As:

Actonel; 1-Hydroxy-2-(3-pyridyl)ethylidene diphosphonate; 2-(3-pyridinyl)-1-hydroxyethylidene-bisphosphonate; 2-(3-pyridinyl)-1-hydroxyethylidenebisphosphonate; Atelvia; Risedronate; Risedronate Sodium; Risedronic Acid, Monosodium Salt; Risedronate Sodium, Bisphosphonate; Sodium, Bisphosphonate Risedronate; Bisphosphonate Risedronate Sodium; Phosphonic acid, (1-hydroxy-2-(3-pyridinyl)ethylidene)bis-

Networked: 916 relevant articles (141 outcomes, 289 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Iwamoto, Jun: 29 articles (01/2019 - 10/2003)
2.	Sato, Yoshihiro: 19 articles (01/2019 - 03/2005)
3.	Takeda, Tsuyoshi: 17 articles (05/2021 - 10/2003)
4.	Boonen, Steven: 15 articles (01/2014 - 09/2004)
5.	Eastell, Richard: 12 articles (01/2019 - 04/2004)
6.	Geusens, Piet: 9 articles (01/2020 - 01/2009)
7.	Marin, Fernando: 9 articles (01/2020 - 03/2008)
8.	Watts, Nelson B: 9 articles (09/2011 - 01/2002)
9.	Hagino, Hiroshi: 8 articles (01/2020 - 05/2009)
10.	Sugimoto, Toshitsugu: 8 articles (01/2020 - 01/2005)

Related Diseases

1.	Osteoporosis 01/01/2009 - "Sustained efficacy of risedronate in men with primary and secondary osteoporosis: results of a 2-year study." 12/01/2020 - "Administering 75 mg of risedronate once a month remains a favorable compliance rate and may be useful for the treatment of patients, even the elderly, with osteoporosis in daily practice." 06/01/2008 - "Monotherapy with alfacarcidol was effective for secondary osteoporosis in children, but when used in combination with risedronate it was even more effective in improving BMD. " 09/01/2014 - "Also in male and steroidal osteoporosis, clinical controlled studies have shown that risedronate is effective in decreasing vertebral fracture incidence. " 01/01/2006 - "At a hypothetical threshold value of euro 40,000 per QALY gained, the results in this study indicate that risedronate is a cost-effective treatment in elderly women at the threshold of osteoporosis (i.e., a T-score of -2.5) with prevalent vertebral fractures in Sweden, Finland, Belgium, and Spain."
2.	Postmenopausal Osteoporosis 07/01/2015 - "Oral risedronate is effective in the treatment of postmenopausal osteoporosis when administered daily, weekly, or monthly. " 01/01/2013 - "Risedronate is effective in the treatment of postmenopausal osteoporosis in oral daily, weekly, or on two consecutive days per month doses. " 01/01/2008 - "Risedronate has been shown to be effective in the treatment of postmenopausal osteoporosis when given orally in daily or weekly doses or on 2 consecutive days per month. " 01/01/2003 - "Based on this analysis, risedronate is a cost-effective treatment for postmenopausal osteoporosis within the German health care system, offering benefits for osteoporotic patients and for budget decision-makers." 04/01/2002 - "Risedronate is an effective and safe option for the treatment of postmenopausal osteoporosis. "
3.	Bone Resorption 01/01/2007 - "At the spine, however, this correlation exists down to a 40% fall in bone resorption markers; larger drops did not provide further protection against fractures in patients taking risedronate in one evaluation of this relationship. " 09/01/2014 - "Under the metabolic profile, these studies have also shown that risedronate activity can reduce bone resorption markers and increase bone density values at lumbar and femoral level. " 12/05/2019 - "Risedronate sodium (RS) is a potent inhibitor of bone resorption, having an extreme poor permeability and limited oral bioavailability (0.62%). " 06/07/2018 - "Oral risedronate could significantly reduce peri-prosthetic bone resorption around an uncemented femoral stem (Gruen zone 1) after THA. " 04/17/2018 - "Oral risedronate could significantly reduce periprosthetic bone resorption around an uncemented femoral stem (Gruen zones 1, 2, 3, 6, and 7) up to 6 months after THA. "
4.	Hip Fractures (Intertrochanteric Fractures) 01/01/2022 - "Risedronate 5 mg/day probably prevents non-vertebral fractures [RR 0.80 (95% CI 0.72 to 0.90; six studies, 12,173 participants); RRR 20% (95% CI 10% to 28%) and ARR 2% fewer (95% CI 1% fewer to 3% fewer), moderate certainty], and may reduce hip fractures [RR 0.73 (95% CI 0.56 to 0.94); RRR 27% (95% CI 6% to 44%) and ARR 1% fewer (95% CI 0.2% fewer to 1% fewer), low certainty]. " 03/12/2007 - "Risedronate for the prevention of hip fractures: concern about validity of trials." 08/01/2002 - "Clinical studies conducted in Japan, North America and/or Europe revealed that risedronate reduces the risks of hip fractures and vertebral fractures by around 30% and around 50% compared with placebo over three years, respectively, and increases lumber spine BMD by around 5% at one year after starting treatment. " 02/01/2012 - "New hip fractures were significantly less frequent in the risedronate group, suggesting a preventive effect in high-risk patients. " 12/01/2011 - "The RR for hip fractures in the risedronate group as compared with the placebo group was 0.20 (95% CI 0.06 to 0.66). "
5.	Pain (Aches) 03/01/2014 - "The mean pain score based on the visual analogue scale showed significant reduction in the risedronate group compared with the control group. " 01/01/1998 - "In summary, 30 mg/day of oral risedronate given in 3 month course significantly reduced the biochemical indices of disease activity, showing normalization of ALP in the majority of patients with severe Paget's disease, and was associated with a significant reduction in pagetic bone pain. " 02/12/2001 - "Risedronate decreases pagetic bone pain and induces radiological improvement in pagetic lesions. " 01/01/2013 - "The two largest studies were conducted with risedronate in the treatment of knee OA, for which meta-analyses were performed for pain and functional outcomes. " 12/01/2011 - "By 24 months, 7/17 risedronate patients vs 0/19 placebo patients stopped the study medication due to bone pain. "

Related Drugs and Biologics

1.	Alendronate (Alendronate Sodium)
2.	Diphosphonates (Bisphosphonates)
3.	Zoledronic Acid (Zometa)
4.	Teriparatide (Parathar)
5.	Glucocorticoids
6.	Etidronic Acid (HEDP)
7.	Calcium
8.	Vitamin D
9.	Ibandronic Acid (Boniva)
10.	Raloxifene Hydrochloride (Evista)

Related Therapies and Procedures

1.	Therapeutics
2.	Oral Administration
3.	Hip Replacement Arthroplasty (Total Hip Replacement)
4.	Drug Therapy (Chemotherapy)
5.	Aftercare (After-Treatment)